GJA1 and prostate cancer: Fukushima et al. showed that therapy with a combination of a Cx43-expressing plasmid and docetaxel enhanced tumour suppression in human prostate cancer cell cultures by increasing the activity of apoptotic molecules and downregulating Bcl-2 expression [138].